免疫检查点抑制剂在头颈部肿瘤中的研究进展  

Research progress of immune checkpoint inhibitors in head and neck cancer

作　　者：刘瑛[1] 黄念[1] 

机构地区：[1]湖北省荆门市第一人民医院肿瘤科二病区,湖北荆门448000

出　　处：《中国医药导报》2016年第30期52-55,共4页China Medical Herald

摘　　要：免疫检查点治疗是一种通过调节免疫系统使其攻击肿瘤细胞的治疗策略。大多数免疫检查点通过免疫细胞表面的蛋白来调节T细胞的反应。程序性死亡受体-1、细胞毒性T淋巴细胞抗原-4作为研究最热的免疫检查点,其相应抗体在抗肿瘤治疗方面取得了临床疗效,并已被批准用于黑色素瘤、非小细胞肺癌和肾恶性肿瘤中。头颈部鳞状细胞癌(HNSCC)是一类以免疫抑制为特征的恶性肿瘤,且免疫系统在HNSCC肿瘤形成中发挥着至关重要的作用。因此,深入探究免疫治疗,特别是免疫检查点抑制剂在HNSCC中的疗效具有重要的临床意义。The immune checkpoint therapy is a strategy that aims to regulate the immune system to effectively attack cancer cells. Most of the immune checkpoints that regulate the T-cell responsesoperate through proteins present on the cytoplasmic membrane of the immune cells. Programmed death 1 （PD-1） and cytotoxic T lymphocyte antigen 4 （CTLA- 4） are the hottest immune checkpoint, the corresponding antibodies have achieved clinical significance in anti-cancer and have been approved in melanoma, non small cell lung cancer and renal cell cancer. Head and neck squamous cell carcinoma （HNSCC） is a group of malignancies characterized by immunosuppression. It is believed that the immune system plays a key role in tumorigenesis of HNSCC. Therefore, there is an important clinical significance to study the effect of immunotherapy, especially the immune checkpoint inhibitor, in HNSCC.

关 键 词：程序性死亡受体-1 细胞毒性T淋巴细胞抗原-4 程序性死亡配体-1 头颈部肿瘤 免疫治疗 

分 类 号：R739.91[医药卫生—肿瘤]